Envista Holdings Corporation (NYSE:NVST – Get Free Report) has received an average recommendation of “Moderate Buy” from the fifteen analysts that are covering the company, MarketBeat reports. Seven equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. The average 1-year target price among brokerages that have covered the stock in the last year is $27.75.
Several research firms have recently weighed in on NVST. Weiss Ratings raised Envista from a “sell (d)” rating to a “hold (c-)” rating in a research report on Tuesday, February 17th. Zacks Research raised Envista from a “hold” rating to a “strong-buy” rating in a research note on Friday, February 6th. Evercore reiterated an “outperform” rating and issued a $32.00 target price on shares of Envista in a report on Friday, February 6th. William Blair raised Envista from a “hold” rating to an “outperform” rating in a research note on Friday, February 6th. Finally, Mizuho increased their price target on Envista from $24.00 to $27.00 and gave the stock a “neutral” rating in a report on Tuesday, February 10th.
Read Our Latest Stock Analysis on NVST
Insider Activity
Hedge Funds Weigh In On Envista
A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Ariel Investments LLC raised its stake in Envista by 1.7% during the 2nd quarter. Ariel Investments LLC now owns 12,355,666 shares of the company’s stock worth $241,430,000 after buying an additional 210,921 shares during the period. Dimensional Fund Advisors LP grew its stake in Envista by 0.9% in the fourth quarter. Dimensional Fund Advisors LP now owns 9,628,460 shares of the company’s stock valued at $209,036,000 after acquiring an additional 90,586 shares during the period. Alliancebernstein L.P. grew its stake in Envista by 34.0% in the second quarter. Alliancebernstein L.P. now owns 6,098,445 shares of the company’s stock valued at $119,164,000 after acquiring an additional 1,547,656 shares during the period. Clarkston Capital Partners LLC increased its holdings in shares of Envista by 0.4% during the second quarter. Clarkston Capital Partners LLC now owns 4,703,330 shares of the company’s stock valued at $91,903,000 after acquiring an additional 16,583 shares in the last quarter. Finally, Massachusetts Financial Services Co. MA raised its position in shares of Envista by 15.3% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 3,349,874 shares of the company’s stock worth $72,726,000 after purchasing an additional 444,725 shares during the period.
Envista Trading Up 0.8%
NYSE:NVST opened at $26.01 on Wednesday. Envista has a 52 week low of $14.22 and a 52 week high of $30.42. The company has a debt-to-equity ratio of 0.47, a quick ratio of 2.04 and a current ratio of 2.38. The firm’s fifty day moving average is $26.51 and its 200-day moving average is $22.83. The firm has a market cap of $4.26 billion, a P/E ratio of 92.91, a P/E/G ratio of 1.76 and a beta of 0.95.
Envista (NYSE:NVST – Get Free Report) last announced its earnings results on Thursday, February 5th. The company reported $0.38 earnings per share for the quarter, topping analysts’ consensus estimates of $0.32 by $0.06. Envista had a net margin of 1.73% and a return on equity of 6.54%. Envista’s revenue was up 15.0% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.24 earnings per share. Envista has set its FY 2026 guidance at 1.350-1.450 EPS. Equities analysts expect that Envista will post 1 earnings per share for the current year.
Envista Company Profile
Envista Holdings Corporation is a global dental products company that develops, manufactures and markets a broad portfolio of dental consumables, equipment and technology solutions. Headquartered in Brea, California, Envista serves dental practitioners, specialists and laboratories in more than 150 countries. The company’s offerings span implant, orthodontic, endodontic and restorative product lines as well as digital imaging systems and practice management software.
Envista’s product brands include Nobel Biocare for dental implants and restorative solutions, Ormco for orthodontic appliances and treatment systems, Kerr for restorative and endodontic materials, KaVo for dental imaging and handpieces, and Vista for surgical drills and instruments.
Further Reading
Receive News & Ratings for Envista Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Envista and related companies with MarketBeat.com's FREE daily email newsletter.
